CRISPR Therapeutics AG (CRSP)Healthcare | Biotechnology | Zug, Switzerland | NasdaqGM
57.99 USD
+2.27
(4.074%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 58.05 +0.06 (0.103%) ⇧ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:18 a.m. EDT
CRSP is a polarizing biotech play. Fundamentally, the company is in distress with negative revenue growth (-97.6%) and significant annualized cash burn (-$205M FCF), causing the long-term hold to be weak (1 star). While analysts rate it a 'Buy' on a turnaround narrative targeting 2026, today’s price action is chaotic. The short-term technicals are mixed; while the monthly close is approaching the 50-day average, the forecasting model predicts a -2.6% move in the next 45 days, and the options market is heavily hedged against downside. This is a speculative hold suitable only for deep-value patients, not a reliable income or momentum vehicle. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.080866 |
| AutoETS | 0.080867 |
| AutoTheta | 0.080901 |
| MSTL | 0.086021 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 60% |
| H-stat | 1.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.351 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.758 |
| Revenue per Share | 0.039 |
| Market Cap | 5,566,188,544 |
| Forward P/E | -13.85 |
| Beta | 1.79 |
| Website | https://www.crisprtx.com |
As of April 19, 2026, 1:18 a.m. EDT: Options flow shows weak bullish conviction. May '26 calls exhibit significant volume and open interest (OI) at strikes above the current price (59, 60, 61), with notable flow at 63. However, this is heavily countered by massive put OI at lower strikes (40-50 range). Notably, the 6-month and 1-year data shows a massive put wall at 75 and 80 strikes respectively, alongside high IV spikes, suggesting a bearish hedge or cap on upside expectations from traders. The short-term IV is elevated, indicating fear or anticipated volatility, but the net positioning (casting a wide net for downside via out-of-the-money puts) suggests skepticism about an immediate rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.53331566 |
| Address1 | Baarerstrasse 14 |
| All Time High | 220.2 |
| All Time Low | 11.63 |
| Ask | 59.08 |
| Ask Size | 14 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 1,560,400 |
| Average Daily Volume3 Month | 1,894,532 |
| Average Volume | 1,894,532 |
| Average Volume10Days | 1,560,400 |
| Beta | 1.794 |
| Bid | 57.33 |
| Bid Size | 14 |
| Board Risk | 9 |
| Book Value | 20.041 |
| City | Zug |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 57.99 |
| Current Ratio | 13.316 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 59.145 |
| Day Low | 57.05 |
| Debt To Equity | 10.758 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -548,838,976 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.918 |
| Enterprise To Revenue | 1,081.797 |
| Enterprise Value | 3,797,106,176 |
| Eps Current Year | -4.94016 |
| Eps Forward | -4.18786 |
| Eps Trailing Twelve Months | -6.47 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 51.9382 |
| Fifty Day Average Change | 6.0518 |
| Fifty Day Average Change Percent | 0.11651924 |
| Fifty Two Week Change Percent | 53.331566 |
| Fifty Two Week High | 78.48 |
| Fifty Two Week High Change | -20.490002 |
| Fifty Two Week High Change Percent | -0.26108563 |
| Fifty Two Week Low | 33.03 |
| Fifty Two Week Low Change | 24.960003 |
| Fifty Two Week Low Change Percent | 0.75567675 |
| Fifty Two Week Range | 33.03 - 78.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,476,883,800,000 |
| Float Shares | 95,554,338 |
| Forward Eps | -4.18786 |
| Forward P E | -13.847168 |
| Free Cashflow | -205,623,744 |
| Full Exchange Name | NasdaqGM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -494,776,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.048839998 |
| Held Percent Institutions | 0.73310995 |
| Implied Shares Outstanding | 95,985,312 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. |
| Long Name | CRISPR Therapeutics AG |
| Market | us_market |
| Market Cap | 5,566,188,544 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_262549448 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -581,598,976 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,566,188,242 |
| Number Of Analyst Opinions | 23 |
| Open | 57.35 |
| Operating Cashflow | -345,014,016 |
| Operating Margins | -179.125 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 41 41 561 32 77 |
| Post Market Change | 0.05999756 |
| Post Market Change Percent | 0.1034619 |
| Post Market Price | 58.05 |
| Post Market Time | 1,776,470,359 |
| Previous Close | 55.72 |
| Price Eps Current Year | -11.738487 |
| Price Hint | 2 |
| Price To Book | 2.8935683 |
| Price To Sales Trailing12 Months | 1,585.8087 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.25 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 2.27 |
| Regular Market Change Percent | 4.07394 |
| Regular Market Day High | 59.145 |
| Regular Market Day Low | 57.05 |
| Regular Market Day Range | 57.05 - 59.145 |
| Regular Market Open | 57.35 |
| Regular Market Previous Close | 55.72 |
| Regular Market Price | 57.99 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,800,015 |
| Return On Assets | -0.15761 |
| Return On Equity | -0.30181998 |
| Revenue Growth | -0.976 |
| Revenue Per Share | 0.039 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 95,985,312 |
| Shares Percent Shares Out | 0.2356 |
| Shares Short | 22,618,060 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 21,562,457 |
| Short Name | CRISPR Therapeutics AG |
| Short Percent Of Float | 0.2643 |
| Short Ratio | 10.01 |
| Source Interval | 15 |
| Symbol | CRSP |
| Target High Price | 291.0 |
| Target Low Price | 33.0 |
| Target Mean Price | 83.34783 |
| Target Median Price | 80.0 |
| Total Cash | 1,975,827,968 |
| Total Cash Per Share | 20.585 |
| Total Debt | 206,746,000 |
| Total Revenue | 3,510,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 56.55055 |
| Two Hundred Day Average Change | 1.4394531 |
| Two Hundred Day Average Change Percent | 0.025454273 |
| Type Disp | Equity |
| Volume | 1,800,015 |
| Website | https://www.crisprtx.com |
| Zip | 6,300 |